News

News

For more information about the history of the company and our technology, click here.

 
November 12, 2020
Talaris Therapeutics Expands Leadership Team with Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations
BOSTON, Mass., and LOUISVILLE, Ky., November 12, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies...  READ MORE
October 6, 2020
Talaris Therapeutics Closes $115 Million Series B Financing
Proceeds to support ongoing Phase 3 registration trial of Talaris’ lead product candidate FCR001 in living donor kidney transplant, and...  READ MORE
September 14, 2020
Talaris Therapeutics Announces Collaboration with Kentucky Organ Donor Affiliates to Advance Preclinical Study of Tolerance Induction to Organs from Deceased Donors
BOSTON, Mass., and LOUISVILLE, Ky., September 14, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies...  READ MORE
July 22, 2020
Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
– Enrollment continues with multiple trial sites now opening across the U.S. – BOSTON, Mass., and LOUISVILLE, Ky., July 22,...  READ MORE
July 8, 2020
FDA Approves Talaris Therapeutics’ IND for its Allogeneic Cell Therapy FCR001 to be Evaluated in Patients with a Severe Form of Scleroderma
BOSTON, Mass., and LOUISVILLE, Ky., July 8, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
May 29, 2020
Update on Talaris’ Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress
– Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ – BOSTON, Mass., May 29, 2020...  READ MORE
December 6, 2019
Talaris Therapeutics to Present at American Society of Hematology (ASH) Annual Meeting
BOSTON, Mass., and LOUISVILLE, Ky., Dec. 6, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
November 7, 2019
Talaris Therapeutics Presents Data Supporting Potential of FCR001 to Prevent Recurrence of Kidney-Related Autoimmune Disease in Kidney Transplant Recipients
BOSTON, Mass., and LOUISVILLE, Ky., Nov. 7, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
October 23, 2019
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
Pivotal trial to evaluate the safety and efficacy of novel, investigational cell therapy intended to durably free living donor kidney...  READ MORE
September 26, 2019
Talaris Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
BOSTON, Mass., and LOUISVILLE, Ky., Sept. 26, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
September 18, 2019
Talaris Therapeutics Wins 2019 “Big Idea” Xconomy Award
BOSTON, Mass., and LOUISVILLE, Ky., September 18, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
June 2, 2019
Talaris Therapeutics Presents Data Demonstrating Improved Quality of Life for Patients Treated with FCR001
BOSTON, Mass., and LOUISVILLE, Ky., June 2, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell...  READ MORE
April 18, 2019
Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
Financing will support Phase 3 trial of FCR001 for living donor kidney transplant patients and additional Phase 2 studies in...  READ MORE
April 18, 2019
Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients
FCR001 established durable immune tolerance in 70% of patients Results support initiation of Phase 3 registration study later this year...  READ MORE